Overweight and obesity are associated with worse cancer outcomes and prognosis. Adipose tissue surrounding tumors, called cancer-associated adipocytes, secrete inflammatory molecules like IL-6 that can promote tumor growth, invasion, and metastasis. In obese conditions, adipose tissue develops a pro-inflammatory state characterized by immune cell infiltration and cytokine expression. This inflamed environment may further enhance cancer-associated adipocytes' effects on tumor progression. Targeting inflammation in adipose tissue, such as with IL-6 blocking antibodies, could potentially improve cancer treatment outcomes, especially in obese patients where adipose tissue inflammation is increased.